Zsuzsanna Suba’s Post

New insights about kidney cancer biomarkers: "The analysis of T-cell receptors within the blood and tumor showed that sunitinib led to higher T-cell counts associated with longer progression-free survival, while avelumab plus axitinib resulted in greater changes in T-cell receptor repertoire and higher clonality. In the tumor, higher T cells were associated with better progression-free survival with immune therapy" Which patients benefit most from TKI vs IO/TKI"? More information to come in renal cancer. So there's more than IMDC risk criteria??

Twenty years ago, our laboratory reported a synergistic interaction between trastuzumab and pertuzumab, monoclonal antibodies directed against different epitopes of the extracellular domain of HER2. This combinaion is now the standard of care in early-stage and metastatic HER2-positive breast cancer. Discover how these groundbreaking targeted biological therapies and antibody-drug conjugates like Enhertu are revolutionizing the treatment of HER2-positive breast cancer and solid tumors. Another example of targeted biological therapy is Gleevec, a drug that target specific genetic abnormalities in chronic myelogenous leukemia and gastrointestinal stromal tumors. Explore the genetic frontier in cancer treatment at my new website, https://lnkd.in/eDvj_ZBJ #TargetedTherapy #BiologicalTherapy #CancerTreatment #HER2Positive #SolidTumors #MonoclonalAntibodies #AntibodyDrugConjugates #Leukemia #GIST #GeneticAbnormalities

Test Using Routine Pap Smears Could Diagnose Ovarian Cancer Early

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.

Test Using Routine Pap Smears Could Diagnose Ovarian Cancer Early

How much do you know about antibody-drug conjugates (ADCs) for cancer therapy? ⬇️ Take a minute to read this post to learn the top 5 facts you should be aware of: [Fact 1] While there are many different ADCs in preclinical and clinical development, 11 are currently approved as cancer treatments. [Fact 2] By targeting delivery of antineoplastic agents only to cells that have certain target antigens, ADCs can help improve the balance between efficacy and toxicity. [Fact 3] Binding to a target cell, followed by #intracellular processing and payload release, are key components of the complex mechanism of action of ADCs. [Fact 4] The unique pharmacodynamic properties of ADCs can be relevant to specific cancers. [Fact 5] Decades of research have helped analyze the full clinical potential of ADCs. Clinical trials continue to be prudently designed to find the most appropriate patients who could benefit from a given treatment. #cancerresearch #cancergoals

I had the opportunity to present our clinical data in prostate cancer during the spotlight session of the EACR/ACCR congress in Dublin. Our findings demonstrate that oncolytic virus ORCA-010, as a first-line treatment, can initiate systemic tumor-specific responses and notably enhance immune cell infiltration into tumors, thereby shifting the microenvironment from cold to hot. I would like to thanks the organizers for providing this opportunity and to all participants for engaging in insightful discussions. #cancerresearch #oncolyticvirus #prostatecancer #immunotherapy ORCA Therapeutics

Prostate Specific Antigen (PSA) is a protein produced by cells in the prostate gland. PSA levels can be measured through a blood test called the PSA test. The PSA test is commonly used as a screening tool for prostate cancer, as well as for monitoring prostate health and evaluating the effectiveness of prostate cancer treatment. PSA testing is an important tool for the early detection of prostate cancer, but it is not without limitations. It's essential to consider PSA test results in the context of individual risk factors, medical history, and preferences, and to discuss screening recommendations and follow-up care with healthcare providers. Early detection and appropriate management can significantly improve outcomes and reduce mortality from prostate cancer.

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J. Seager, Sarabjot Pabla, and our Labcorp team evaluated patients with advanced non-small cell lung cancer (NSCLC), treated with chemoimmunotherapy or immunotherapy alone, who underwent comprehensive genomic and immune profiling. Patients with a high CTA burden score and who were treated with immunotherapy had improved overall survival compared to those with low CTA burden score. There was significant co-expression of CTAB with tumor mutational burden, but, not with PD-L1. CTA burden is a potential biomarker of immunotherapy response and warrants further exploration.